Long lasting complete molecular remission after suspending dasatinib treatment in chronic myeloid le...
Long lasting complete molecular remission after suspending dasatinib treatment in chronic myeloid leukemia
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Tyrosine kinase inhibitors specific for BCR-ABL, were a major breakthrough in CML therapy. Second generation tyrosine kinase inhibitors (dasatinib, nilotinib) are indicated for imatinib resistant and intolerant patients. Present guidelines recommend continuous drug dosing for maintaining remission. There is no available data concerning the optimal...
Alternative Titles
Full title
Long lasting complete molecular remission after suspending dasatinib treatment in chronic myeloid leukemia
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_6e683dd3ded245448f316853ca5bf160
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_6e683dd3ded245448f316853ca5bf160
Other Identifiers
ISSN
2162-3619
E-ISSN
2162-3619
DOI
10.1186/2162-3619-1-17
